H. R. 6—113 
SEC. 6104. REVISING MEASURES USED UNDER THE HOSPITAL CON-
SUMER ASSESSMENT OF HEALTHCARE PROVIDERS AND 
SYSTEMS SURVEY RELATING TO PAIN MANAGEMENT. 
(a) RESTRICTION ON THE USE OF PAIN QUESTIONS IN HCAHPS.— 
Section 1886(b)(3)(B)(viii) of the Social Security Act (42 U.S.C. 
1395ww(b)(3)(B)(viii)) is amended by adding at the end the following 
new subclause: 
‘‘(XII)(aa) With respect to a Hospital Consumer Assessment 
of Healthcare Providers and Systems survey (or a successor survey) 
conducted on or after January 1, 2020, such survey may not include 
questions about communication by hospital staff with an individual 
about such individual’s pain unless such questions take into 
account, as applicable, whether an individual experiencing pain 
was informed about risks associated with the use of opioids and 
about non-opioid alternatives for the treatment of pain. 
‘‘(bb) The Secretary shall not include on the Hospital Compare 
internet website any measures based on the questions appearing 
on the Hospital Consumer Assessment of Healthcare Providers 
and Systems survey in 2018 or 2019 about communication by hos-
pital staff with an individual about such individual’s pain.’’. 
(b) RESTRICTION ON USE OF 2018 AND 2019 PAIN QUESTIONS 
IN
THE HOSPITAL VALUE-BASED PURCHASING PROGRAM.—Section 
1886(o)(2)(B) of the Social Security Act (42 U.S.C. 1395ww(o)(2)(B)) 
is amended by adding at the end the following new clause: 
‘‘(iii) HCAHPS PAIN
QUESTIONS.—The Secretary 
may not include under subparagraph (A) a measure 
that is based on the questions appearing on the Hos-
pital Consumer Assessment of Healthcare Providers 
and Systems survey in 2018 or 2019 about communica-
tion by hospital staff with an individual about the 
individual’s pain.’’. 
Subtitle L—Fighting the Opioid Epidemic 
With Sunshine 
SEC. 6111. FIGHTING THE OPIOID EPIDEMIC WITH SUNSHINE. 
(a) INCLUSION OF INFORMATION REGARDING PAYMENTS TO ADDI-
TIONAL PRACTITIONERS.— 
(1) IN GENERAL.—Section 1128G(e)(6) of the Social Security 
Act (42 U.S.C. 1320a–7h(e)(6)) is amended— 
(A) in subparagraph (A), by adding at the end the 
following new clauses: 
‘‘(iii) A physician assistant, nurse practitioner, or 
clinical nurse specialist (as such terms are defined 
in section 1861(aa)(5)). 
‘‘(iv) A certified registered nurse anesthetist (as 
defined in section 1861(bb)(2)). 
‘‘(v) A certified nurse-midwife (as defined in section 
1861(gg)(2)).’’; and 
(B) in subparagraph (B), by inserting ‘‘, physician 
assistant, nurse practitioner, clinical nurse specialist, cer-
tified nurse anesthetist, or certified nurse-midwife’’ after 
‘‘physician’’. 
(2) EFFECTIVE DATE.—The amendments made by this sub-
section shall apply with respect to information required to
H. R. 6—114 
be submitted under section 1128G of the Social Security Act 
(42 U.S.C. 1320a–7h) on or after January 1, 2022. 
(b) SUNSET OF EXCLUSION OF NATIONAL PROVIDER IDENTIFIER 
OF COVERED RECIPIENT IN INFORMATION MADE PUBLICLY AVAIL-
ABLE.—Section 1128G(c)(1)(C)(viii) of the Social Security Act (42 
U.S.C. 1320a–7h(c)(1)(C)(viii)) is amended by striking ‘‘does not 
contain’’ and inserting ‘‘in the case of information made available 
under this subparagraph prior to January 1, 2022, does not contain’’. 
(c) ADMINISTRATION.—Chapter 35 of title 44, United States 
Code, shall not apply to this section or the amendments made 
by this section. 
TITLE VII—PUBLIC HEALTH 
PROVISIONS 
Subtitle A—Awareness and Training 
SEC. 7001. REPORT ON EFFECTS ON PUBLIC HEALTH OF SYNTHETIC 
DRUG USE. 
(a) IN GENERAL.—Not later than 3 years after the date of 
the enactment of this Act, the Secretary of Health and Human 
Services, in coordination with the Surgeon General of the Public 
Health Service, shall submit to the Committee on Energy and 
Commerce of the House of Representatives and the Committee 
on Health, Education, Labor, and Pensions of the Senate a report 
on the health effects of new psychoactive substances, including 
synthetic drugs, used by adolescents and young adults. 
(b) NEW PSYCHOACTIVE SUBSTANCE DEFINED.—For purposes 
of subsection (a), the term ‘‘new psychoactive substance’’ means 
a controlled substance analogue (as defined in section 102(32) of 
the Controlled Substances Act (21 U.S.C. 802(32)). 
SEC. 7002. FIRST RESPONDER TRAINING. 
Section 546 of the Public Health Service Act (42 U.S.C. 290ee– 
1) is amended— 
(1) in subsection (c)— 
(A) in paragraph (2), by striking ‘‘and’’ at the end; 
(B) in paragraph (3), by striking the period and 
inserting ‘‘; and’’; and 
(C) by adding at the end the following: 
‘‘(4) train and provide resources for first responders and 
members of other key community sectors on safety around 
fentanyl, carfentanil, and other dangerous licit and illicit drugs 
to protect themselves from exposure to such drugs and respond 
appropriately when exposure occurs.’’; 
(2) in subsection (d), by striking ‘‘and mechanisms for 
referral to appropriate treatment for an entity receiving a grant 
under this section’’ and inserting ‘‘mechanisms for referral to 
appropriate treatment, and safety around fentanyl, carfentanil, 
and other dangerous licit and illicit drugs’’; 
(3) in subsection (f)— 
(A) in paragraph (3), by striking ‘‘and’’ at the end; 
(B) in paragraph (4), by striking the period and 
inserting ‘‘; and’’; and 
(C) by adding at the end the following:
H. R. 6—115 
‘‘(5) the number of first responders and members of other 
key community sectors trained on safety around fentanyl, 
carfentanil, and other dangerous licit and illicit drugs.’’; 
(4) by redesignating subsection (g) as subsection (h); 
(5) by inserting after subsection (f) the following: 
‘‘(g) OTHER KEY COMMUNITY SECTORS.—In this section, the 
term ‘other key community sectors’ includes substance use disorder 
treatment providers, emergency medical services agencies, agencies 
and organizations working with prison and jail populations and 
offender reentry programs, health care providers, harm reduction 
groups, pharmacies, community health centers, tribal health facili-
ties, and mental health providers.’’; and 
(6) in subsection (h), as so redesignated, by striking 
‘‘$12,000,000 for each of fiscal years 2017 through 2021’’ and 
inserting ‘‘$36,000,000 for each of fiscal years 2019 through 
2023’’. 
Subtitle 
B—Pilot 
Program 
for 
Public 
Health Laboratories To Detect Fentanyl 
and Other Synthetic Opioids 
SEC. 7011. PILOT PROGRAM FOR PUBLIC HEALTH LABORATORIES TO 
DETECT FENTANYL AND OTHER SYNTHETIC OPIOIDS. 
(a) GRANTS.—The Secretary of Health and Human Services 
(referred to in this section as the ‘‘Secretary’’) shall award grants 
to, or enter into cooperative agreements with, Federal, State, and 
local agencies to improve coordination between public health labora-
tories and laboratories operated by law enforcement agencies, such 
as Customs and Border Protection and the Drug Enforcement 
Administration, to improve detection of synthetic opioids, including 
fentanyl and its analogues, as described in subsection (b). 
(b) DETECTION ACTIVITIES.—The Secretary, in consultation with 
the Director of the National Institute of Standards and Technology, 
the Director of the Centers for Disease Control and Prevention, 
the Attorney General of the United States, and the Administrator 
of the Drug Enforcement Administration, shall, for purposes of 
this section, develop or identify— 
(1) best practices for safely handling and testing synthetic 
opioids, including fentanyl and its analogues, including with 
respect to reference materials, instrument calibration, and 
quality control protocols; 
(2) reference materials and quality control standards 
related to synthetic opioids, including fentanyl and its ana-
logues, to enhance— 
(A) clinical diagnostics; 
(B) postmortem data collection; and 
(C) portable testing equipment utilized by law enforce-
ment and public health officials; and 
(3) procedures for the identification of new and emerging 
synthetic opioid formulations and procedures for reporting those 
findings to appropriate law enforcement agencies and Federal, 
State, and local public health laboratories and health depart-
ments, as appropriate. 
(c) LABORATORIES.—The Secretary shall require recipients of 
grants or cooperative agreements under subsection (a) to—
H. R. 6—116 
(1) follow the best practices established under subsection 
(b) and have the appropriate capabilities to provide laboratory 
testing of controlled substances, such as synthetic fentanyl, 
and biospecimens for the purposes of aggregating and reporting 
public health information to Federal, State, and local public 
health officials, laboratories, and other entities the Secretary 
deems appropriate; 
(2) work with law enforcement agencies and public health 
authorities, as practicable; 
(3) provide early warning information to Federal, State, 
and local law enforcement agencies and public health authori-
ties regarding trends or other data related to the supply of 
synthetic opioids, including fentanyl and its analogues; 
(4) provide biosurveillance capabilities with respect to 
identifying trends in adverse health outcomes associated with 
non-fatal exposures; and 
(5) provide diagnostic testing, as appropriate and prac-
ticable, for non-fatal exposures of emergency personnel, first 
responders, and other individuals. 
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry out this sec-
tion, there is authorized to be appropriated $15,000,000 for each 
of fiscal years 2019 through 2023. 
Subtitle C—Indexing Narcotics, Fentanyl, 
and Opioids 
SEC. 7021. ESTABLISHMENT OF SUBSTANCE USE DISORDER INFORMA-
TION DASHBOARD. 
Title XVII of the Public Health Service Act (42 U.S.C. 300u 
et seq.) is amended by adding at the end the following new section: 
‘‘SEC. 1711. ESTABLISHMENT OF SUBSTANCE USE DISORDER INFORMA-
TION DASHBOARD. 
‘‘(a) IN GENERAL.—Not later than 6 months after the date 
of the enactment of this section, the Secretary of Health and Human 
Services shall, in consultation with the Director of National Drug 
Control Policy, establish and periodically update, on the Internet 
website of the Department of Health and Human Services, a public 
information dashboard that— 
‘‘(1) provides links to information on programs within the 
Department of Health and Human Services related to the reduc-
tion of opioid and other substance use disorders; 
‘‘(2) provides access, to the extent practicable and appro-
priate, to publicly available data, which may include data from 
agencies within the Department of Health and Human Services 
and— 
‘‘(A) other Federal agencies; 
‘‘(B) State, local, and Tribal governments; 
‘‘(C) nonprofit organizations; 
‘‘(D) law enforcement; 
‘‘(E) medical experts; 
‘‘(F) public health educators; and 
‘‘(G) research institutions regarding prevention, treat-
ment, recovery, and other services for opioid and other 
substance use disorders;